- Researchers show overall vaccine efficacy of 70.4% from a pooled analysis of two-dose regimen
- No hospitalisations or severe disease observed in the vaccinated groups from three weeks after first dose
- Efficacy results are based on data taken from 11,636 volunteers across the United Kingdom and Brazil
- Data are first Phase 3 trial results of a coronavirus vaccine to be published in peer-review literature
The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
The efficacy data are based on 11,636 volunteers across the United Kingdom and Brazil, and combined across three groups of people vaccinated – two groups who received a standard dose prime vaccination followed by a standard dose booster vaccination and one group (in the UK only) who received a low dose prime vaccination followed by a standard dose vaccination.